Abstract

BackgroundThalidomide is an immunomodulatory agent, which arrests angiogenesis. The mechanism of anti-angiogenic activity of thalidomide is not fully understood. As nitric oxide is involved in angiogenesis, we speculate a cross-talk between thalidomide and nitric oxide signaling pathway to define angiogenesis. The aim of present study is to understand the mechanistic aspects of thalidomide-mediated attenuation of angiogenesis induced by nitric oxide at the cellular level.MethodsTo study the cellular mechanism of thalidomide-mediated blocking of angiogenesis triggered by nitric oxide, we used two endothelial cell based models: 1) wound healing and 2) tube formation using ECV 304, an endothelial cell line. These cell-based models reflect pro-angiogenic events in vivo. We also studied the effects of thalidomide on nitric oxide mediated egg yolk angiogenesis. Thalidomide could block the formation of blood vessels both in absence and presence of nitric oxide. Thalidomide effects on migration of, and actin polymerization in, ECV 304 cells were studied at the single cell level using live cell imaging techniques and probes to detect nitric oxide.ResultsResults demonstrate that thalidomide blocks nitric oxide-mediated angiogenesis in egg yolk model and also reduces the number of tubes formed in endothelial cell monolayers. We also observed that thalidomide arrests wound healing in presence and absence of nitric oxide in a dose-dependent fashion. Additionally, thalidomide promotes actin polymerization and antagonizes the formation of membrane extensions triggered by nitric oxide in endothelial cells. Experiments targeting single tube structure with thalidomide, followed by nitric oxide treatment, show that the tube structures are insensitive to thalidomide and nitric oxide. These observations suggest that thalidomide interferes with nitric oxide-induced migration of endothelial cells at the initial phase of angiogenesis before cells co-ordinate themselves to form organized tubes in endothelial cells and thereby inhibits angiogenesis.ConclusionThalidomide exerts inhibitory effects on nitric oxide-mediated angiogenesis by altering sub-cellular actin polymerization pattern, which leads to inhibition of endothelial cell migration.

Highlights

  • Thalidomide is an immunomodulatory agent, which arrests angiogenesis

  • Our study indicates that thalidomide attenuates Nitric oxide (NO)-driven angiogenesis by blocking migration of endothelial cells (EC) even before any tube structure had been formed, which further hints an interaction between thalidomide and NO signaling

  • sodium nitroprusside (SNP) treatments of ECs caused an increase in the number of high actin polymerization (high AP) cells, an effect that was reversed by thalidomide (25, 50 and 75 μg/ml) in a dosedependent manner

Read more

Summary

Introduction

Thalidomide is an immunomodulatory agent, which arrests angiogenesis. Thalidomide, α-(N-phthalimido) glutarimide is an immunomodulatory agent, which is used as a drug to treat multiple myeloma and other types of cancers [1]. The drug thalidomide, first synthesized in 1954 [2,3], was widely prescribed to treat morning sickness in pregnant women in the early 60s. Thalidomide became anathema when it was found to be seriously teratogenic having caused serious birth defects in more than 10,000 newborns. As scientists probed further into the causes for teratogenicity, they realized the innate potency of this drug to treat other diseases [4]. In August 1998, Food and Drug Administration (FDA) approved Thalidomide for sale in the USA for chronic treatment of erythema nodosum leprosum (ENL), a painful inflammatory dermatological reaction of lepromatous leprosy [4]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call